中东和非洲癫痫市场预测至 2030 年 - 区域分析 - 按类型（渐进性肌阵挛性癫痫、反射性癫痫、全身性癫痫等）、给药途径（口服、肠胃外等）、治疗类型（第一代药物、第二代药物和第三代药物）、年龄组（成人和儿童）和分销渠道（医院药房、零售药房等）
基因疗法作为有前途的治疗方法，促进了中东和非洲癫痫市场的发展
基因疗法正在被探索作为某些遗传性癫痫的潜在治疗选择。这种创新方法旨在通过修改或操纵细胞的基因组成来治疗疾病。基因治疗的基本原理是纠正或替换导致特定疾病发展或进展的缺陷基因。由于癫痫发作是由器官特定部位的脑细胞活动（神经元）过度引起的，因此针对这些神经元并关闭它们可以帮助预防癫痫发作。可以采用两种标准基因治疗技术来设计癫痫治疗，即基因添加和基因编辑。基因添加涉及向个体细胞添加遗传物质以平衡缺失或异常的基因，而基因编辑则涉及通过直接修改个体的基因来治疗遗传性癫痫。通过针对与癫痫相关的特定基因并操纵细胞遗传物质，基因治疗可以帮助恢复正常细胞功能并抑制癫痫发作。
检查疾病的遗传原因使医疗保健提供者能够提供更加个性化和有针对性的治疗方法。在涉及可遗传突变的病例中，这些知识有助于了解受影响家庭的风险并促进遗传咨询，然后做出明智的决策。在识别导致癫痫的遗传因素方面不断取得进展，在指导受影响个体的医疗护理和管理方面发挥着至关重要的作用。下一代测序在很大程度上推动了遗传学领域的重大进展。这种高通量基因测序技术能够更快、更全面地分析 DNA，从而有助于识别癫痫等疾病的遗传原因。
基因研究的持续进展有可能改善对癫痫患者及其家人的护理和支持。通过针对与离子通道、神经递质受体或细胞信号通路相关的基因，研究人员可以研究这些基因的改变如何导致癫痫发生。
尽管癫痫的基因治疗仍处于早期发展阶段，但动物模型的临床前研究已显示出令人鼓舞的结果。具有特定癫痫相关基因突变的动物模型已使用基因治疗方法进行治疗，从而降低了癫痫发作频率并改善了癫痫发作控制。2023 年 12 月，伦敦大学学院皇后广场神经病学研究所的研究人员开发了一种新的基因疗法来治疗一种毁灭性的儿童癫痫，这种疗法已被证明可以显着减少小鼠的癫痫发作。他们评估了一种基于过度表达钾通道的基因疗法，该钾通道控制额叶局灶性皮质发育不良的小鼠模型中的神经元兴奋性。研究人员将一种名为 EKC 的工程化钾通道基因注射到癫痫小鼠受影响的额叶中。他们使用一种缺乏复制能力的病毒作为携带钾通道基因的载体。研究人员发现，与对照组相比，基因疗法平均降低了 87% 的癫痫发作，而不会改变小鼠的记忆或行为。考虑到癫痫治疗中尚未满足的需求，它可以用于治疗受到不受控制的癫痫发作严重影响的儿童。
许多用于治疗癫痫的基因治疗试验目前正在进行或处于计划阶段。这些试验的目的是评估基因疗法对患有特定遗传形式癫痫的人类患者的安全性和有效性。它是一种基于 AAV 的基因疗法，有可能提高药物耐药性局灶性癫痫患者的生活质量，目前尚无有效的治疗方法。候选治疗药物 CG01 使用基因治疗载体将神经肽 Y 及其受体 Y2 的组合直接递送到触发癫痫发作的大脑区域。
因此，基因治疗很可能成为未来几年癫痫市场的一个有前途的新趋势。
中东和非洲癫痫市场概览
MEA 的癫痫市场进一步细分为阿联酋、沙特阿拉伯、南非和 MEA 其他地区。MEA 国家癫痫的中位患病率为每 1,000 人中有 7 人。最常见的与癫痫发展风险增加相关的风险因素包括近亲结婚、癫痫家族史和围产期感染史。
中东和非洲癫痫市场收入及预测至 2030 年（百万美元）
中东和非洲癫痫市场细分
中东和非洲癫痫市场分为类型、给药途径、治疗类型、年龄组、分销渠道和国家。
根据类型，中东和非洲癫痫市场分为进行性肌阵挛性癫痫、反射性癫痫、全身性癫痫和其他。全身性癫痫部分在 2022 年占据最大市场份额。
就给药途径而言，中东和非洲癫痫市场分为口服、肠外和其他。口服部分在 2022 年占据最大市场份额。
按治疗类型，中东和非洲癫痫市场分为第一代药物、第二代药物和第三代药物。第三代药物部分在 2022 年占据了最大的市场份额。
根据年龄组，中东和非洲癫痫市场分为成人和儿童。成人部分在 2022 年占据了更大的市场份额。
在分销渠道方面，中东和非洲癫痫市场分为医院药房、零售药房和其他。医院药房部分在 2022 年占据了最大的市场份额。
按国家/地区划分，中东和非洲癫痫市场分为沙特阿拉伯、南非、阿联酋和中东及非洲其他地区。 2022 年，中东和非洲其他地区占据了中东和非洲癫痫市场的主导份额。
雅培实验室、辉瑞公司、卫材株式会社、UCB SA、LivaNova Plc、诺华公司、美敦力公司、葛兰素史克公司和 H. Lundbeck AS 是中东和非洲癫痫市场的一些领先公司。
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Middle East & Africa Pipeline Studies for Epilepsy Therapy Approaches
4.1 Pipeline Studies for Epilepsy Therapy Approaches
4.1.1 Cell and Gene Therapy Approaches
4.1.2 Encapsulated cell bio delivery (ECB) system
4.1.3 Gene Therapy for Epilepsy Clinical Overview
4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
4.1.3.1.1 Gene Supplementation - Overview
4.1.3.1.2 Gene Modulation - Overview
4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
4.1.3.1.4 Neuropeptides - Overview
4.1.3.1.5 Engineered Channels - Overview
4.1.3.1.6 Endogenous Channels - Overview
4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
4.1.3.7 Enzyme Inducing Antiepileptic Drugs
5. Middle East & Africa Epilepsy Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Epilepsy
5.1.2 Increasing Investments in Development of Epilepsy Therapies
5.2 Market Restraints
5.2.1 Recall of Products
5.3 Market Opportunities
5.3.1 Surge in Awareness Programs Conducted by Organizations
5.4 Future Trends
5.4.1 Gene Therapy as Promising Treatment Approach
5.5 Impact of Drivers and Restraints:
6. Epilepsy Market - Middle East & Africa Analysis
6.1 Middle East & Africa: Epilepsy Market
7. Middle East & Africa Epilepsy Market Analysis - by Type
7.1 Overview
7.2 Progressive Myoclonic Epilepsy
7.2.1 Overview
7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Reflex Epilepsy
7.3.1 Overview
7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Generalized Epilepsy
7.4.1 Overview
7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Other
7.5.1 Overview
7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8. Middle East & Africa Epilepsy Market Analysis - by Route of Administration
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9. Middle East & Africa Epilepsy Market Analysis - by Treatment Type
9.1 Overview
9.2 First Generation Drugs
9.2.1 Overview
9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Second Generation Drugs
9.3.1 Overview
9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Third Generation Drugs
9.4.1 Overview
9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10. Middle East & Africa Epilepsy Market Analysis - by Age Group
10.1 Overview
10.2 Adult
10.2.1 Overview
10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
10.3 Children
10.3.1 Overview
10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11. Middle East & Africa Epilepsy Market Analysis - by Distribution Channel
11.1 Overview
11.2 Hospital Pharmacies
11.2.1 Overview
11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.3 Retail Pharmacies
11.3.1 Overview
11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
11.4 Others
11.4.1 Overview
11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12. Middle East & Africa Epilepsy Market - Country Analysis
12.1 Middle East & Africa Epilepsy Market Overview
12.1.1 Middle East & Africa: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
12.1.1.1 Saudi Arabia: Epilepsy Market Overview
12.1.1.2 Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.2.1 Saudi Arabia: Epilepsy Market Breakdown, by Type
12.1.1.2.2 Saudi Arabia: Epilepsy Market Breakdown, by Route of Administration
12.1.1.2.3 Saudi Arabia: Epilepsy Market Breakdown, by Treatment Type
12.1.1.2.4 Saudi Arabia: Epilepsy Market Breakdown, by Age Group
12.1.1.2.5 Saudi Arabia: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.3 South Africa: Epilepsy Market Overview
12.1.1.4 South Africa: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.4.1 South Africa: Epilepsy Market Breakdown, by Type
12.1.1.4.2 South Africa: Epilepsy Market Breakdown, by Route of Administration
12.1.1.4.3 South Africa: Epilepsy Market Breakdown, by Treatment Type
12.1.1.4.4 South Africa: Epilepsy Market Breakdown, by Age Group
12.1.1.4.5 South Africa: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.5 United Arab Emirates: Epilepsy Market Overview
12.1.1.6 United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.6.1 United Arab Emirates: Epilepsy Market Breakdown, by Type
12.1.1.6.2 United Arab Emirates: Epilepsy Market Breakdown, by Route of Administration
12.1.1.6.3 United Arab Emirates: Epilepsy Market Breakdown, by Treatment Type
12.1.1.6.4 United Arab Emirates: Epilepsy Market Breakdown, by Age Group
12.1.1.6.5 United Arab Emirates: Epilepsy Market Breakdown, by Distribution Channel
12.1.1.7 Rest of Middle East & Africa: Epilepsy Market Overview
12.1.1.8 Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
12.1.1.8.1 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Type
12.1.1.8.2 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Route of Administration
12.1.1.8.3 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Treatment Type
12.1.1.8.4 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Age Group
12.1.1.8.5 Rest of Middle East & Africa: Epilepsy Market Breakdown, by Distribution Channel
13. Industry Landscape
13.1 Overview
13.2 Growth Strategies in Epilepsy Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Abbott Laboratories
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Pfizer Inc
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Eisai Co Ltd
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 UCB SA
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 LivaNova Plc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
14.6 Novartis AG
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Products and Services
14.6.4 Financial Overview
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Medtronic Plc
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Products and Services
14.7.4 Financial Overview
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 GSK Plc
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Products and Services
14.8.4 Financial Overview
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 H. Lundbeck AS
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Products and Services
14.9.4 Financial Overview
14.9.5 SWOT Analysis
14.9.6 Key Developments
15. Appendix
15.1 About The Insight Partners
List of Tables
Table 1. Middle East & Africa Epilepsy Market Segmentation
Table 2. Cell Therapy Approach - An Overview
Table 3. Gene Therapy Approach - An Overview
Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
Table 5. Preclinically Tested Genetic Therapies for Epilepsy
Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
Table 7. Viral Vectors Comparison with respect to Various Parameters
Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
Table 9. Enzyme-Inducing Antiepileptic Drugs
Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Target Types Overview
Table 11. Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 12. Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 13. Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 14. Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 15. Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 16. South Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 17. South Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. South Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 19. South Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 20. South Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 21. United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 23. United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 24. United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 25. United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 26. Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 27. Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 28. Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
Table 29. Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
Table 30. Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 31. Recent Organic Growth Strategies in Epilepsy Market
Table 32. Recent Inorganic Growth Strategies in the Epilepsy Market
List of Figures
Figure 1. Middle East & Africa Epilepsy Market Segmentation, by Country
Figure 2. Epilepsy Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Middle East & Africa: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Middle East & Africa: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Saudi Arabia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. South Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. United Arab Emirates: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Rest of Middle East & Africa: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
Figure 31. Growth Strategies in Epilepsy Market
- Abbott Laboratories
- Pfizer Inc
- Eisai Co Ltd
- UCB SA
- LivaNova Plc
- Novartis AG
- Medtronic Plc
- GSK Plc
- H. Lundbeck AS
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Middle East & Africa epilepsy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa epilepsy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the Middle East & Africa epilepsy market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.